` AUTL (Autolus Therapeutics PLC) vs S&P 500 Comparison - Alpha Spread

AUTL
vs
S&P 500

Over the past 12 months, AUTL has underperformed S&P 500, delivering a return of -30% compared to the S&P 500's +16% growth.

Stocks Performance
AUTL vs S&P 500

Loading
AUTL
S&P 500
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
AUTL vs S&P 500

Loading
AUTL
S&P 500
Difference
www.alphaspread.com

Performance By Year
AUTL vs S&P 500

Loading
AUTL
S&P 500
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Autolus Therapeutics PLC vs Peers

S&P 500
AUTL
ABBV
AMGN
GILD
VRTX
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Autolus Therapeutics PLC
Glance View

Market Cap
425.8m USD
Industry
Biotechnology

Autolus Therapeutics Plc is a biopharmaceutical company, which engages in the development and commercialization of gene therapies. The firm is focused on developing programmed T cell therapies for the treatment of cancer. The firm has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors. Its lead clinical programs include AUTO1 (obecabtagene autoleucel, Obe-Cel), AUTO4, and AUTO6 / AUTO6NG. Obe-cel is a CD19 CAR T cell investigational therapy designed to overcome limitations in clinical activity and safety. Obe-cel reduces toxicity and is less prone to T cell exhaustion, which could improve persistence and the ability of programmed T cells to engage in serial killing of target cancer cells. AUTO4 is a T cell therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1. AUTO6 / AUTO6NG is a T cell therapy targeting GD2 in development for the treatment of neuroblastoma. Its other clinical programs include AUTO5, AUTO7, and AUTO8.

AUTL Intrinsic Value
10.02 USD
Undervaluation 84%
Intrinsic Value
Price
Back to Top